ניקסואה תשתתף בכנס הבריאות של בנק אוף אמריקה לשנת
2026
מונט-סן-גיבר, בלגיה – 30 באפריל 2026, GLOBE NEWSWIRE
–
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המפתחת חלופות טיפול פורצות דרך לדום נשימה חסימתי בשינה (OSA), הודיעה היום כי החברה תשתתף בכנס הבריאות של Bank of America 2026 ביום רביעי, 13 במאי 2026. החברה צפויה להציג בשעה 17:15 שעון ET באותו
יום באמצעות שידור אינטרנט.
Nyxoah to Participate in the Bank of America
2026 Healthcare Conference
Mont-Saint-Guibert, Belgium – April 30, 2026, GLOBE NEWSWIRE
–
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of innovative
solutions to treat Obstructive Sleep Apnea (OSA), today announced that the
Company will participate in the Bank of America 2026 Healthcare Conference on
Wednesday, May 13th, 2026. The Company is scheduled to present at
5:15pm Eastern Time the same day via webcast.
A live audio webcast of Nyxoah’s presentation at the conference can be
accessed through this LINK. The Company will be
available for 1x1 meetings with institutional investors attending the event.
About Nyxoah
Nyxoah is a medical technology company focused on the development and
commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution
is the Genio system, a patient-centered, leadless and battery-free hypoglossal
neurostimulation therapy for OSA, the world’s most common sleep disordered
breathing condition that is associated with increased mortality risk and
cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio
system received its European CE Mark in 2019. Nyxoah completed two successful
IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following
the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to Complete
Concentric Collapse (CCC) patients, currently contraindicated in competitors’
therapy. Additionally, the Company announced positive outcomes from the DREAM
IDE pivotal study and receipt of approval from the FDA for a subset of adult
patients with moderate to severe OSA with an AHI of greater than or equal to 15
and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as
prescription-only device.
תגובות
הוסף רשומת תגובה